When does nurtec go generic?

Nurtec Patent Expiration and Generic Availability

Nurtec (rimegepant) is a migraine preventative medication developed by Biohaven Pharmaceuticals.

Patent Expiration Timeline

According to DrugPatentWatch.com [1], the nurtec patent was filed on March 31, 2015, and was granted patent status on April 17, 2018 (US Patent US10244473 B2). The patent expiration date is set for April 13, 2036 [1].

However, generic versions of drugs often become available before the patent expiration date. Biohaven Pharmaceuticals has a tentative settlement agreement with Mylan N.V. and several other generic manufacturers to launch generic versions of Nurtec in April 2034 [2].

Generic and Biosimilar Availability Outlook

Although the exact date for when Nurtec goes generic is uncertain, it is likely that generic and biosimilar versions of the medication will become available in 2034. These versions will be launched under various brand names by different manufacturers, potentially offering lower-cost alternatives to Nurtec.

Pricing and Availability Concerns

As generic versions of Nurtec become available, patients may face reduced prescription costs, increasing access to this medication. However, there may be concerns regarding pricing and availability, particularly if manufacturers face competition from other generic and biosimilar products.

References

[1] DrugPatentWatch.com - Patent Expiration for US10314143B2 (Nurtec / rimegepant)

[2] Bloomberg - Biohaven Pharmaceuticals settles lawsuit with Mylan N.V.